Did you know? National practice guidelines currently recommend ALL women with metastatic (HER2-) breast cancer to get genetic testing for inherited cancer (including BRCA1/2 testing), because it can guide eligibility for treatment with PARP inhibitors.
A new study led by our colleague at the Vanderbilt-Ingram Cancer Center, Dr. Ben Park, suggests that more women with metastatic breast cancer have BRCA1/2 mutations than previously thought. In fact, of the 100 women with metastatic breast cancer tested through this study, 6% had BRCA1/2 mutations!
Findings from this study highlight the importance of genetic testing for ALL women with metastatic breast cancer to help guide their treatment, AND further guide risk management for themselves and their at-risk family members.
Check out the study at the following link: https://www.ncbi.nlm.nih.gov/pubmed/31465090